The groundbreaking success of the copyright undeniably reshaped the drug landscape, but placing funds in companies strongly reliant on unbranded versions presents a challenging picture. While early returns were impressive, the expiration of patents and the rise of cheaper alternatives have eroded sales. Consequently, a thorough analysis of present